July 1, 2025
Nature Communications

Deep learning assessment of metastatic relapse risk from digitized breast cancer histological slides

AI
Biology
Cancer
RlapsRisk BC
Diagnostics
Clinical Validation
Breast Cancer
Abstract

Accurate risk stratification is critical for guiding treatment decisions in early breast cancer. We present an artificial intelligence (AI)-based tool that analyzes digitized tumor slides to predict 5-year metastasis-free survival (MFS) in patients with estrogen receptor-positive, HER2-negative (ER + /HER2 − ) early breast cancer (EBC).

Our deep learning model, RlapsRisk BC, independently predicts MFS and provides significant prognostic value beyond traditional clinico-pathological variables (C-index 0.81 vs 0.76, p < 0.05). Applying a 5% MFS event probability threshold stratifies patients into low- and high-risk groups. After dichotomization, combining RlapsRisk BC with clinico- pathological factors increases cumulative sensitivity (0.69 vs 0.63) and dynamic specificity (0.80 vs 0.76) compared to clinical factors alone. Expert analysis of high-impact regions identified by the model highlights well- established morphological features, supporting its interpretability and biolo- gical relevance.

Authors
Ingrid Garberis
Valentin Gaury
Charlie Saillard
Damien Drubay
Kevin Elgui
Benoit Schmauch
Alexandre Jaeger
Loic Herpin
Julia Linhart
M. Sapateiro
F. Bernigole
Alexandre Filiot
Oussama Tchita
Remy Dubois
Michaël Auffret
Lionel Guillou
Imad Bousaid
Mikael Azoulay
Jerome Lemonnier
Meriem Sefta, PhD
S. Everhard
A. Sarrazin
Jean-François Reboud
Fabien Brulport
Jocelyn Dachary
Barbara Pistilli
Suzette Delaloge
Pierre Courtiol
Prof. Fabrice André, MD, PhD
Victor Aubert
Magali Lacroix-Triki, M.D., PhD